Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.